2 completed, 1 terminated. 3 Phase 2, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Completed 2, Terminated 1 |
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow Inmunova S.A.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study to Assess Safety, Efficacy, and Pharmacokinetics of INM004 in Pediatric Patients With STEC-HUS INM004, SoC - Diarrhea-Associated Hemolytic Uremic Syndrome, Pediatric Kidney Disease | Phase 2 | Completed | Inmunova S.A. | 57 | 2022-10-06 | 2023-08-21 |
| A Study to Investigate the Pharmacokinetics, Efficacy and Safety of INM005 in Patients With COVID-19. INM005, Placebo - COVID-19 | Phase 2 / Phase 3 | Completed | Inmunova S.A. | 243 | 2020-07-27 | 2026-04-20 |
| Phase 2/3 Study to Evaluate PK, Safety & Efficacy of INM004 in STEC Positive Pediatric Patients for Prevention of HUS INM004, Placebo - Bloody Diarrhea, STEC, Unspecified | Phase 2 / Phase 3 | Terminated | Inmunova S.A. | 11 | 2019-07-17 | 2023-07-19 |
Hemolytic-Uremic Syndrome (2) · COVID-19 (1)
Exercise (1)
Argentina (3)
Fernando Goldbaum, PhD (1) · Santiago Sanguineti, Ph.D. (1)
PMID 33870149, PMID 34013969, PMID 34219224, PMID 34473343, PMID 40277027, PMID 41757982